IsoPlexis has raised an additional $20 million in its Series C financing, bringing the entire Series C round to $45 million. The funding will continue to drive the global commercial expansion of its IsoLight single-cell proteomic analysis platform.
IsoPlexis has recently expanded its operational, manufacturing, and commercial team across the US, Europe, and Asia, with 130 employees. The IsoLight single-cell system is used globally by leading biotech, pharma, and academic medical centers to solve critical challenges in cell therapy, cancer immunology, and inflammatory disease. more